Moderna patents nucleic acid vaccine for varicella zoster virus

Summary: Moderna has patented a nucleic acid vaccine for varicella zoster virus, utilizing mRNA encoding VZV glycoproteins and a lipid nanoparticle. GlobalData reports Moderna's grant share at 27% in February 2024. The patent details lipid nanoparticle variations and chemically modified mRNA for enhanced efficacy. This innovative vaccine technology could revolutionize immunization strategies. For more insights, GlobalData offers a comprehensive report on Moderna's patenting strategy.

Full article